Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

Fig. 3

Influence of PIK3CA and ERBB mutations and phosphatase and tensin homolog (PTEN) expression status on pathological complete response (pCR) rates using a χ2 test of association. The proportion of patients who obtained pCR is shown for the entire patient cohort. Phosphatidylinositol 3-kinase (PI3K) activation is defined as the presence of one or more of the following in a breast tumour: PIK3CA or ERBB family mutations or low PTEN expression. WT Wild type

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us